ADVISORY, March 10, 2014 (GLOBE NEWSWIRE) --
Cara Therapeutics, Inc. [CARA], a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, will visit the NASDAQ MarketSite in Times Square.The Cara team, led by President and CEO Dr. Derek Chalmers, will ring the Opening Bell in honor of the company's recent initial public offering. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Tuesday, March 11, 2014 – 9:15 a.m. to 9:30 a.m. ET Contact : Jesse Baumgartner (212) 362-1200 firstname.lastname@example.org Tony Plohoros (908) 940-0135 tplohoros@6degreesPR.com NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com Feed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Social Media: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ. For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq. For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx. For exciting viral content and ceremony photos visit our Tumblr Page: http://nasdaq.tumblr.com/. Webcast: A LiveStream of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live Or http://www.nasdaq.com/about/marketsitetowervideo.asx. Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice. About Cara Therapeutics, Inc. [CARA]: Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.